ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure-Reference-Cited by-同舟云学术

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure

Published:2017-07-31 Issue:18 Volume:1 Page:1369-1381
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Marum Justine E.¹²,Yeung David T.¹³⁴⁵,Purins Leanne⁶,Reynolds John⁷,Parker Wendy T.⁸,Stangl Doris¹,Wang Paul P. S.⁸,Price David J.⁹,Tuke Jonathan⁹,Schreiber Andreas W.⁸,Scott Hamish S.¹⁵⁸¹⁰¹¹,Hughes Timothy P.³⁴¹⁰,Branford Susan¹⁵¹⁰¹¹

Affiliation:

1. Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;

2. Division of Health Sciences, University of South Australia, Adelaide, Australia;

3. Department of Haematology, SA Pathology, Adelaide, Australia;

4. Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia;

5. School of Medicine, University of Adelaide, Adelaide, Australia;

6. Department of Haematology Cellular Therapies, SA Pathology, Adelaide, Australia;

7. Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia;

8. Australian Cancer Research Foundation Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;

9. School of Mathematical Sciences, University of Adelaide, Adelaide, Australia;

10. School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia; and

11. School of Biological Sciences, University of Adelaide, Adelaide, Australia

Abstract

Key Points Germ line variants in ASXL1 and BIM are strong biomarkers of response to imatinib in chronic phase CML. A combined Sokal risk and ASXL1 and BIM variant model identified a subgroup of patients with the greatest risk of treatment failure.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/18/1369/878348/advances006825.pdf

Reference52 articles.

1. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia;Hughes;N Engl J Med,2003

2. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV;Kalmanti;Leukemia,2015

3. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial;Hochhaus;Leukemia,2016

4. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial;Cortes;J Clin Oncol,2016

5. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib;Blood Neoplasia;2024-06

2. Chronic myeloid leukaemia: Biology and therapy;Blood Reviews;2024-05

3. Additional prognostic value of polymorphisms within the 3′-untranslated region of programmed cell death pathway genes in early-stage breast cancer;Frontiers in Immunology;2024-04-16

4. Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients;Gene;2023-11

5. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia;Leukemia;2023-10-04